Pemvidutide
The Muscle-Sparing GLP-1/Glucagon Dual Agonist
Pemvidutide (ALT-801) is Altimmune's once-weekly dual agonist targeting both GLP-1 and glucagon receptors. Its standout feature: DEXA scan data from the MOMENTUM trial shows superior lean mass preservation compared to semaglutide — making it the GLP-1 of choice for users who don't want to sacrifice muscle.
What Is Pemvidutide?
Pemvidutide (development names ALT-801 and AZD9550) is being developed by Altimmune in partnership with AstraZeneca. It is a balanced dual agonist of the GLP-1 receptor and the glucagon receptor (GCGR), administered as a once-weekly subcutaneous injection.
The GLP-1 component suppresses appetite and slows gastric emptying — the same mechanism as semaglutide (Ozempic/Wegovy). The glucagon component adds a distinct thermogenic effect: it increases metabolic rate, enhances fat oxidation, and promotes fat clearance from the liver. Together, these two pathways produce weight loss that is both significant and qualitatively different from pure GLP-1 monotherapy.
Why it matters: The glucagon component drives fat loss preferentially, which is why DEXA scan data from MOMENTUM showed pemvidutide users retaining lean muscle mass at rates superior to semaglutide. For patients focused on body composition — not just the number on the scale — this distinction is critical.
MOMENTUM Phase 2b Trial Results
The MOMENTUM Phase 2b trial evaluated pemvidutide across multiple dose groups over 24 weeks, with DEXA body composition scans providing objective muscle vs. fat data at baseline and end-of-study.
Participants on the 1.2mg weekly dose lost an average of 10.7% of body weight at 24 weeks. Higher doses demonstrated up to 15.6% weight loss, consistent with a clear dose-response relationship.
DEXA scan comparisons showed pemvidutide participants maintained lean body mass significantly better than those on semaglutide. The glucagon-driven preferential fat oxidation is the likely mechanism — glucagon signals the body to pull energy from fat stores rather than muscle protein.
At higher doses, the 24-week weight loss approached 15.6%. The Phase 3 ADVANCE trial will run for a longer duration — typical GLP-1 trials show continued weight loss through 52-72 weeks, suggesting final Phase 3 numbers will be considerably higher.
The Dual Mechanism: GLP-1 + Glucagon
GLP-1 Receptor Agonism
- • Suppresses appetite centrally and peripherally
- • Slows gastric emptying — prolongs satiety
- • Improves glucose-stimulated insulin secretion
- • Reduces fasting and postprandial glucose
- • Proven cardiovascular protective effects
Glucagon Receptor (GCGR) Agonism
- • Increases basal metabolic rate (thermogenic effect)
- • Enhances fat oxidation — burns fat preferentially
- • Promotes hepatic fat clearance (MASH potential)
- • Improves lipid profiles (LDL, triglycerides)
- • Spares lean muscle mass during weight loss
Why the Combination Outperforms Either Alone
GLP-1 alone reduces calories in. Glucagon receptor activation increases calories out by raising metabolic rate. Together, pemvidutide attacks obesity from both ends of the energy balance equation — while the GLP-1 component prevents the glucagon from raising blood sugar, making the pairing metabolically safe.
Muscle Preservation: Why Pemvidutide Is Different
One of the most significant concerns with GLP-1 medications like semaglutide is muscle loss. On average, 25-40% of total weight lost on semaglutide is lean mass, not fat — raising concerns about long-term metabolic health, strength, and weight regain after discontinuation.
Pemvidutide's DEXA scan data directly addressed this concern. By comparing body composition changes — not just total weight — the MOMENTUM trial provided objective evidence that pemvidutide shifts the composition of weight loss toward fat, sparing muscle.
The mechanism is logical: glucagon receptor activation signals adipose tissue to release stored fat as fuel. When more energy comes from fat stores, the body has less need to catabolize muscle protein. This makes pemvidutide particularly attractive for physically active individuals, older patients concerned about sarcopenia, or anyone who prioritizes body composition over raw weight loss numbers.
MASH / Liver Disease Potential
Beyond weight loss and muscle preservation, pemvidutide is being studied for MASH (metabolic dysfunction-associated steatohepatitis) — formerly called NASH. This is the progressive form of fatty liver disease that can advance to cirrhosis and liver failure.
The glucagon receptor plays a well-established role in hepatic (liver) fat metabolism. GCGR activation directly reduces liver fat accumulation by promoting fat oxidation in hepatocytes and reducing fat synthesis. This same mechanism that spares muscle also clears fat from the liver.
Other GLP-1/glucagon dual agonists like Survodutide have shown remarkable MASH results (83% resolution in Phase 2). Pemvidutide's similar mechanism positions it as a credible candidate for liver disease treatment — though liver-specific Phase 2/3 data is still maturing.
Development Timeline & ADVANCE Phase 3
Pemvidutide vs Other GLP-1/Glucagon Dual Agonists
| Drug | Mechanism | Weight Loss | Muscle Data |
|---|---|---|---|
| Pemvidutide (ALT-801) | GLP-1 + Glucagon | 10.7–15.6% (24 wks) | DEXA: Superior lean mass vs semaglutide |
| Survodutide (BI 456906) | GLP-1 + Glucagon | ~18.7% (46 wks) | Not specifically reported |
| Retatrutide (LY3437943) | GLP-1 + GIP + Glucagon | ~28.7% (68 wks) | Limited published DEXA |
| Semaglutide (Wegovy) | GLP-1 only | ~15–17% (68 wks) | ~25-40% of loss is lean mass |
Frequently Asked Questions
Will pemvidutide raise my blood sugar like regular glucagon?
No. In isolated form, glucagon raises blood sugar — but pemvidutide's GLP-1 component strongly counteracts this by enhancing insulin secretion. MOMENTUM trial data showed no clinically meaningful blood glucose elevation, and participants with prediabetes actually showed improvements in glycemic markers. The pairing is designed to be metabolically safe.
How does pemvidutide's weight loss compare to Zepbound or Wegovy?
At 24 weeks, pemvidutide's 10.7–15.6% weight loss is broadly comparable to semaglutide at similar timepoints. However, direct comparisons are difficult because different trials use different time horizons. What distinguishes pemvidutide is body composition — the quality of weight lost, not just the quantity. Patients on pemvidutide lose proportionally more fat and less muscle.
When will pemvidutide be available?
Pemvidutide is expected to enter Phase 3 ADVANCE trials in 2025–2026. If Phase 3 succeeds, FDA submission could occur in 2027–2028, with potential approval to follow. AstraZeneca's backing provides the resources needed to run large global trials efficiently.